4 patents currently held
64 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next US patent term in the Medical Research Council portfolio ends in Jan 2034, and more of its terms end in 2034 (3) than in any other year. from the record
Of the 64 now held by other companies, 50 name United Kingdom Research and Innovation as their current owner, and 14 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2034
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Apr 2028 · High confidence
Cited by 460 later US patents, top 1% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
now held by United Kingdom Research and Innovation
Also notable
Ends Aug 2030 · High confidence
Cited by 40 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
now held by Bicyclerd Limited
Also notable
Ends Feb 2030 · High confidence
Cited by 25 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Bicyclerd Limited
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 1 term has ended since Aug 24, 2026
- Oct 7 US 8,853,131 Modified Stefin a Scaffold Proteins · lapsed on the fee record
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Self-Inactivating Rabies Virus Vector Encoding a Nucleoprotein and Degron | 1 in force | to Nov 2040 |
| Nanoparticle Formulation | 1 in force | to Jun 2034 |
| ANGIOPOIETIN-2 Specific TIE2 Receptor | 1 in force | to May 2034 |
| Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | 1 in force | to Jan 2034 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,954,198 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases In force · Medium confidence | In force | Medium confidence | |
| US 10,208,100 | ANGIOPOIETIN-2 Specific TIE2 Receptor In force · High confidence | In force | High confidence | |
| US 10,201,499 | Nanoparticle Formulation In force · High confidence | In force | High confidence | |
| US 12,203,092 | Self-Inactivating Rabies Virus Vector Encoding a Nucleoprotein and Degron In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 64 patents in force now held by others · 117 patents ended · 1 application pending · 198 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
26 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
18 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.